Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction

The onset of the bronchodilating effect of formoterol (12 microg by Turbuhaler) was compared with that of salbutamol (50 microg by Turbuhaler), salmeterol (50 microg by Diskhaler) and placebo in methacholine-induced severe bronchoconstriction. Seventeen subjects with mild-to-moderate asthma completed this randomized, double blind, cross-over, double-dummy study. On four study days, baseline forced expiratory volume in one second (FEV1) was recorded and the subjects were challenged with methacholine until FEV1 fell by at least 30%. Immediately thereafter, the study drugs were inhaled and lung function was assessed for 60 min. The geometric mean time for FEV1 to return to 85% of baseline was 7.2 min with formoterol, 6.5 min with salbutamol, 14.1 min with salmeterol and 34.7 min with placebo (p=0.0001, overall ANOVA). The difference between formoterol and salmeterol was statistically significant (p=0.01); there was no difference between formoterol and salbutamol (p=0.69). In conclusion, formoterol reversed methacholine-induced severe bronchoconstriction as rapidly as salbutamol and more rapidly than salmeterol. Classifying beta2-agonists as "fast"- and "slow"- acting may be supplemental to "short"- and "long"-acting.

This article has been cited by other articles:

				M. N. Hermansen, K. G. Nielsen, F. Buchvald, J. J. Jespersen, T. Bengtsson, and H. Bisgaard Acute Relief of Exercise-Induced Bronchoconstriction by Inhaled Formoterol in Children With Persistent Asthma Chest, May 1, 2006; 129(5): 1203 - 1209. [Abstract] [Full Text] [PDF]

				A. R. Rubinfeld, R. Scicchitano, A. Hunt, P. J. Thompson, A. Van Nooten, and O. Selroos Formoterol Turbuhaler as reliever medication in patients with acute asthma Eur. Respir. J., April 1, 2006; 27(4): 735 - 741. [Abstract] [Full Text] [PDF]

				D. Cheung, H. C. J. van Klink, R. Aalbers, and for the OZON study group Improved lung function and symptom control with formoterol on demand in asthma. Eur. Respir. J., March 1, 2006; 27(3): 504 - 510. [Abstract] [Full Text] [PDF]

				H. J. van der Woude, J. Zaagsma, D. S. Postma, T. H. Winter, M. van Hulst, and R. Aalbers Detrimental Effects of {beta}-Blockers in COPD: A Concern for Nonselective {beta}-Blockers Chest, March 1, 2005; 127(3): 818 - 824. [Abstract] [Full Text] [PDF]

				J. Gabrijelcic, A. Casas, R.A. Rabinovich, J. Roca, J.A. Barbera, K.F. Chung, and R. Rodriguez-Roisin Formoterol protects against platelet-activating factor-induced effects in asthma Eur. Respir. J., January 1, 2004; 23(1): 71 - 75. [Abstract] [Full Text] [PDF]

				P.W. Ind, C. Villasante, R.J. Shiner, A. Pietinalho, N.G. Boszormenyi, S. Soliman, and O. Selroos Safety of formoterol by Turbuhaler(R) as reliever medication compared with terbutaline in moderate asthma Eur. Respir. J., October 1, 2002; 20(4): 859 - 866. [Abstract] [Full Text] [PDF]

				K. Richter, S. Janicki, R.A. Jorres, and H. Magnussen Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline Eur. Respir. J., May 1, 2002; 19(5): 865 - 871. [Abstract] [Full Text] [PDF]

				J. A. Nightingale, D. F. Rogers, and P. J. Barnes Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma* Chest, May 1, 2002; 121(5): 1401 - 1406. [Abstract] [Full Text] [PDF]

				J. Malolepszy, G. Boszormenyi Nagy, O. Selroos, P. Larsson, and R. Brander Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction Eur. Respir. J., December 1, 2001; 18(6): 928 - 934. [Abstract] [Full Text] [PDF]

				J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]

				H.J. van der Woude and R. Aalbers Unaltered perception of dyspnoea during treatment with long-acting {beta}2-agonists Eur. Respir. J., August 1, 2001; 18(2): 269 - 271. [Abstract] [Full Text] [PDF]

				H J van der Woude, T H Winter, and R Aalbers Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting {beta}2 agonists Thorax, July 1, 2001; 56(7): 529 - 535. [Abstract] [Full Text] [PDF]

				A R Guhan, S Cooper, J Oborne, S Lewis, J Bennett, and A E Tattersfield Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects Thorax, August 1, 2000; 55(8): 650 - 656. [Abstract] [Full Text]